Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

Liver International

Volumn 35, Issue 11, 2015, Pages 2442-2447

  Saab, Sammy ^a   Greenberg, Adam ^a   Li, Edwin ^a   Bau, Sherona Ngashea ^a   Durazo, Francisco ^a   El Kabany, Mohammed ^a   Han, Steven ^a   Busuttil, Ronald W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral therapy; Hepatitis C; Liver transplant recipients

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN; HEMOGLOBIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; ANTIVIRUS AGENT; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LIVER TRANSPLANTATION; MALE; PNEUMONIA; PORTAL VEIN THROMBOSIS; RECURRENT INFECTION; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE COUNT; URINARY TRACT INFECTION; VIRUS LOAD; AGED; BLOOD; COMBINATION DRUG THERAPY; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; RECURRENT DISEASE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; SIMEPREVIR; SOFOSBUVIR; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84945442148     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12856     Document Type: Article

References (21)

1. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant 2015; 15(Suppl 2): 1-28.
2. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-93.
3. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-83.
4. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-6.
5. Agopian VG, Petrowsky H, Kaldas FM, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg 2013; 258: 409-21.
6. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-62.
7. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16: 748-59.
8. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
9. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132-9.
10. Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859-67.
11. Saab S, Oh MK, Ibrahim AB, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007; 13: 1032-8.
12. Lawitz E, Sulkowski MS. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
13. AASLD/IDSA/IAS-USA. When and in whom to initiate HCV therapy. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org/full-report/when-and-whom-initiate-hcv-therapy. Accessed 7 October 2014.
14. Saab S, Manne V, Bau S, et al. Boceprevir in liver transplant recipients. Liver Int 2015; 35: 192-7.
15. Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
16. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 348: g3308.
17. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-82.
18. Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Presented at: AASLD 2014; 2014 Nov 7-11; Boston, MA.
19. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-17.
20. Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015; 61: 41-5.
21. Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int 2015; 35: 30-6.